• Medicine
  • Published in Oncology 2004

Gemcitabine-containing regimens vs others in first-line treatment of NSCLC.

@article{Natale2004GemcitabinecontainingRV,
  title={Gemcitabine-containing regimens vs others in first-line treatment of NSCLC.},
  author={Ronald B. Natale},
  journal={Oncology},
  year={2004},
  volume={18 8 Suppl 5},
  pages={
          27-31
        }
}
Standard first-line chemotherapy regimens in advanced non-small-cell lung cancer (NSCLC) include carboplatin (Paraplatin)/paclitaxel, cisplatin/docetaxel (Taxotere), cisplatin/gemcitabine (Gemzar), and cisplatin/vinorelbine (Navelbine). An informal meta-analysis of 13 randomized trials of these regimens in NSCLC indicates no marked differences in terms of response rates or survival, but toxicity advantages with cisplatin/gemcitabine and cisplatin/vinorelbine regimens. An informal meta-analysis… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002

Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study.

H. Soto Parra, Raffaele Cavina, +7 authors A. Santoro
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2002